Marcia Hernandez, DO
Gynecologic Oncology · Camden, NJNPI 1902177074
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Genmab U.S., Inc. at 24.8% of the total.
Across 38 payments — averaging $40.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genmab U.S., Inc.$380
- AstraZeneca$332
- Merck$160
- Davol Inc.$135
- GSK$124
- Intuitive Surgical$121
- plus $280 from 8 others
Across 5 payments — averaging $5797.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$17K
- Regeneron$12K
What the payments were for
- Food & beverage$1,49498%
- Education$362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genmab U.S., Inc. | 7 | $380 |
| AstraZeneca | 5 | $332 |
| Merck | 4 | $160 |
| Davol Inc. | 1 | $135 |
| GSK | 5 | $124 |
| Intuitive Surgical | 1 | $121 |
| Eisai Inc. | 7 | $111 |
| AbbVie | 2 | $56 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $24 |
| Immunogen, Inc. | 1 | $18 |
| Tesaro, Inc. | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
| Tempus AI, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TIVDAK$239
- LYNPARZA$236
- Da Vinci Surgical System$121
- KEYTRUDA$114
How this compares
$1,530 in reported general payments places this provider in the 55th percentile of 45 gynecologic oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $7,472 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 47 | $197 |
| Pregabalin | 18 | $82 |
| Ondansetron Hcl | 29 | $70 |
| Gabapentin | 32 | $55 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Camden
- David WarshalCamden$2K
- Christina ChuCamden$2K
- Meredith DuffyCamden$528
- Nida HasanCamden$81
- Sharyn LewinTeaneck$968K
- Scott RichardFlorham Park$84K
- Joyce VarughesePennington$16K
- James BosscherNeptune$13K
- Daniel TobiasMorristown$11K
- Karim ElsahwiNeptune$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.